Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-14FDA Approved: DANZITEN — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Danziten (nilotinib) submitted by Azurity Pharmaceuticals, Inc. The supplement adds to the e…
-
EMA approval · 2026-04-09EMA Authorised: Iclusig (ponatinib) — Incyte Biosciences Distribution B.V.
The European Medicines Agency authorised Iclusig (ponatinib) from Incyte Biosciences Distribution B.V. for certain leukemias, including chro…
-
FDA approval · 2026-04-06FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' supplemental application for Imatinib Mesylate (ANDA 212773), approving a generic version of the cancer…
-
EMA approval · 2026-01-15EMA Authorised: Blincyto (blinatumomab) — Amgen Europe B.V.
The EMA authorised Blincyto (blinatumomab) by Amgen Europe B.V. for precursor cell lymphoblastic leukemia/lymphoma, designated as an orphan …
-
FDA approval · 2025-09-30FDA Approved: DASATINIB — Supplemental Application (Dr.Reddys Laboratories Inc)
The FDA has approved a supplemental application for dasatinib from Dr. Reddy's Laboratories Inc, authorizing an update to the approval of th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-09-17EMA Authorised: Besponsa (Inotuzumab ozogamicin) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Besponsa (inotuzumab ozogamicin) for precursor cell lymphoblastic leukemia-lymphoma under Pfizer Eu…
-
FDA approval · 2025-08-28FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)
The FDA approved Apotex Corp.'s supplemental application for dasatinib (DASATINIB).
-
FDA approval · 2025-08-28FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for dasatinib (generic), enabling the continued availability of a generic DASATINIB thr…
-
FDA approval · 2025-08-01FDA Approved: PHYRAGO — Supplemental Application (Cycle Pharmaceuticals Ltd)
The FDA has approved a supplemental application for PHYRAGO (dasatinib) from Cycle Pharmaceuticals Ltd.
-
FDA approval · 2025-07-10FDA Approved: NILOTINIB — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for nilotinib from Cipla USA Inc., indicating an approved update to the drug's labeling or indic…
-
FDA approval · 2025-06-26FDA Approved: MERCAPTOPURINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for mercaptopurine, enabling continued marketing of the generic p…
-
EMA approval · 2025-05-23New treatment for adults with acute lymphoblastic leukaemia
The EMA approved brexucabtagene autoleucel (Tecartus) for adults with acute lymphoblastic leukemia, marking the third CAR T-cell therapy app…
-
FDA approval · 2025-04-29FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for BLINCYTO (blinatumomab) from Amgen, Inc., updating labeling and/or expanding the approved in…
-
FDA approval · 2025-04-22FDA Approved: DASATINIB — Original Application (Aurobindo Pharma Limited)
FDA approved the original ANDA for dasatinib from Aurobindo Pharma Limited (generic dasatinib).
-
FDA approval · 2025-04-14FDA Approved: IMATINIB MESYLATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' imatinib mesylate as an original (ANDA) generic product.
-
FDA approval · 2025-03-20FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for imatinib mesylate (Teva) under an ANDA, authorizing continued regulatory approval for this gener…
-
FDA approval · 2025-03-03FDA Approved: DASATINIB — Original Application (Biocon Pharma Inc.)
FDA approves Biocon Pharma Inc.'s original application for dasatinib (generic) to treat certain leukemias, marking the availability of a gen…
-
FDA approval · 2025-03-03FDA Approved: DASATINIB — Original Application (Dr.Reddys Laboratories Inc)
FDA approved the original application for dasatinib by Dr. Reddy's Laboratories Inc, providing a generic version of dasatinib for leukemias.…
-
FDA approval · 2025-01-08FDA Approved: IMATINIB MESYLATE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental ANDA for Imatinib Mesylate (Chartwell RX, LLC), enabling marketing of a generic version of the cancer drug.
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
FDA approval · 2024-12-19FDA Approved: CYCLOPHOSPHAMIDE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for cyclophosphamide, establishing a generic version of the chemotherapy agent.
-
FDA approval · 2024-12-09FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for imatinib mesylate from Mylan Pharmaceuticals, effectively authorizing a supplemental approva…
-
FDA approval · 2024-12-03FDA Approved: PHYRAGO — Supplemental Application (Cycle Pharmaceuticals Ltd)
FDA approved a supplemental application for PHYRAGO (dasatinib) submitted by Cycle Pharmaceuticals Ltd.
-
FDA approval · 2024-11-22FDA Approved: IMKELDI — Original Application (Shorla Oncology Inc.,)
FDA approved IMKELDI (imatinib oral) under an original NDA from Shorla Oncology, authorizing a new imatinib product for several cancers incl…
-
FDA approval · 2024-11-07FDA Approved: DANZITEN — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved the Original Application for DANZITEN (nilotinib) from Azurity Pharmaceuticals, establishing a branded nilotinib product for Ph…